Gelesis Holdings, Inc.

For the three months ended September 30, 2022, product revenue was $6.4 million, driven by over 92,000 units sold, and new member acquisitions were 23,500, up 50% from 15,700 in the prior-year quarter. Gross margin rose to 44% from 8% in Q3 2021, producing gross profit of $2.8 million versus $251,000 a year ago. Net loss improved to $14.1 million from $30.7 million, and adjusted EBITDA loss improved to $12.3 million from $26.2 million. On the balance sheet, cash was $24.8 million, receivables were $5.6 million, inventory was $18.4 million, and accounts payable were $8 million. For full-year 2022, management said product revenue, gross profit, and adjusted EBITDA are expected to remain within previously provided guidance, and cost cuts should extend runway into at least Q2 next year.

Yishai Zohar framed Plenity as a differentiated weight-management product with the broadest addressable market because it is cleared for BMI as low as 25 without comorbidities. He emphasized that prescription friction and cost are limiting adoption, and argued that an OTC pathway could make the product more accessible, expand distribution channels, and lower customer acquisition costs. His tone was optimistic and mission-driven, with repeated emphasis on long-term growth, self-sustainability, and becoming less dependent on capital markets.

Elliot Maltz highlighted the quarter’s operating leverage, citing $6.4 million of product revenue, gross margin of 44%, gross profit of $2.8 million, net loss of $14.1 million, and adjusted EBITDA loss of $12.3 million. He said sales and marketing expense fell to $7.3 million in Q3 from $21.2 million in Q1 and $22.2 million in Q2, reflecting deliberate pullback to preserve liquidity. He also pointed to $24.8 million of cash on hand and said additional spending reductions across SG&A, manufacturing, and R&D should extend runway into at least the second quarter of next year, while the equity line of credit would likely be used only modestly and opportunistically.

Analysts focused on the strategic shift to OTC and how it changes Plenity’s commercialization model. Management said the move is intended to reduce prescription friction, reach a larger market, and open new distribution channels, while Ro would remain an important partner and physicians could still recommend or prescribe the product in OTC form. Questions also focused on funding, given the cash balance and burn; the CFO said the company is talking with investors and exploring debt, equity, and partnership options, but expects existing cash plus cost cuts to fund operations into at least Q2 next year.